{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:14:32Z","timestamp":1787886872149,"version":"build-2784847793"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX25 _1050"],"award-info":[{"award-number":["KYCX25 _1050"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577153"],"award-info":[{"award-number":["22577153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20252069"],"award-info":[{"award-number":["BK20252069"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejmech.2026.118887","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:57:21Z","timestamp":1777359441000},"page":"118887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discovery of an orally bioavailable selenium-containing Pol\u03b8 inhibitor with a dual mechanism of DNA damage and immune activation for HR-deficient cancers"],"prefix":"10.1016","volume":"313","author":[{"given":"Luyu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangchi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-4062","authenticated-orcid":false,"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118887_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118887_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.molcel.2016.05.021","article-title":"When genome maintenance goes badly awry","volume":"62","author":"Kass","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118887_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","article-title":"Synthetic lethal strategies for the development of cancer therapeutics","volume":"22","author":"Ngoi","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118887_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","article-title":"Olaparib: first global approval","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118887_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118887_bib6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118887_bib7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.aar5149","article-title":"Beyond PARP-POL\u03b8 as an anticancer target","volume":"359","author":"Higgins","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118887_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118887_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.dnarep.2016.05.003","article-title":"DNA polymerase \u03b8 (POLQ), double-strand break repair, and cancer","volume":"44","author":"Wood","year":"2016","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2026.118887_bib10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nsmb.3494","article-title":"The helicase domain of poltheta counteracts RPA to promote alt-NHEJ","volume":"24","author":"Mateos-Gomez","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118887_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118887_bib12","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1038\/s41467-019-12272-9","article-title":"Molecular basis of microhomology-mediated end-joining by purified full-length Poltheta","volume":"10","author":"Black","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118887_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4216","article-title":"A polymerase theta-dependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites","volume":"5","author":"Koole","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118887_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature14157","article-title":"Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination","volume":"518","author":"Mateos-Gomez","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118887_bib15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41417-024-00815-2","article-title":"Poltheta: emerging synthetic lethal partner in homologous recombination-deficient tumors","volume":"31","author":"Bazan Russo","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejmech.2026.118887_bib16","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.1038\/s41467-023-43446-1","article-title":"Genetic separation of Brca1 functions reveal mutation-dependent Poltheta vulnerabilities","volume":"14","author":"Krais","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118887_bib17","article-title":"Hierarchical coordination of polymerase theta and RAD51 resolves clustered replication fork collapse","author":"Smith","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.118887_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41556-021-00764-0","article-title":"POLtheta-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis","volume":"23","author":"Llorens-Agost","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118887_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-59708-z","article-title":"Dual inhibition of DNA-PK and Pol\u03f4 boosts precision of diverse prime editing systems","volume":"16","author":"Dacquay","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118887_bib20","series-title":"SHLD2 Loss Is a Synthetic Vulnerability to Pol\u03b8 Inhibition Combined with Radiotherapy","author":"Rodriguez-Berriguete","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118887_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-174333","article-title":"Inactivation of DNA polymerase theta (Pol\u0398) is synthetic lethal in DNMT3A mutated myeloid malignancies - potential clinical applications","volume":"142","author":"Le","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118887_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118887_bib23","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Poltheta inhibitors elicit BRCA-Gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118887_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170660","article-title":"Polymerase theta inhibition steps on the cGAS pedal","volume":"133","author":"Smith","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118887_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165934","article-title":"POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS\/STING signaling","volume":"133","author":"Oh","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118887_bib26","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1038\/s41467-024-51351-4","article-title":"Structural basis for a Pol\u03b8 helicase small-molecule inhibitor revealed by cryo-EM","volume":"15","author":"Ito","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118887_bib27","doi-asserted-by":"crossref","first-page":"19726","DOI":"10.1021\/acs.jmedchem.5c02103","article-title":"The discovery of RP-2119: a potent, selective, and orally bioavailable poltheta ATPase inhibitor","volume":"68","author":"Mochirian","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118887_bib28","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.3c02096","article-title":"Discovery and proof of concept of potent dual Poltheta\/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118887_bib29","unstructured":"Artios Pharma Ltd, A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib30","unstructured":"GlaxoSmithKline, A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or with Niraparib in Participants with Solid Tumors, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib31","unstructured":"National Cancer Institute, Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients with Tumors that Have Alterations in DNA Repair Genes, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib32","unstructured":"Artios Pharma Ltd, Study of ART6043 in Advanced\/Metastatic Solid Tumors Patients, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib33","unstructured":"MOMA Therapeutics, Study of Orally Administered MOMA-313 in Participants with Advanced or Metastatic Solid Tumors, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib34","unstructured":"Repare Therapeutics, Phase 1 Trial of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors (POLAR), in."},{"key":"10.1016\/j.ejmech.2026.118887_bib35","unstructured":"Jiangsu Simcere Pharmaceutical Co. Ltd., Study of SIM0508 Alone and in Combination in Patients with Advanced Solid Tumors, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib36","unstructured":"Hangzhou SynRx Therapeutics Biomedical Technology Co. Ltd, Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib37","unstructured":"Danatlas Pharmaceuticals Co. Ltd, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib38","unstructured":"T.A. Yap, First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in Patients with molecularly-selected Advanced Solid Tumors, in."},{"key":"10.1016\/j.ejmech.2026.118887_bib39","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1021\/jm0200815","article-title":"Synthesis, SAR, and biological evaluation of Oximino-Piperidino-Piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent Anti-HIV activity","volume":"45","author":"Palani","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118887_bib40","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1124\/dmd.118.081182","article-title":"Differences in the in vivo and in vitro metabolism of imrecoxib in humans: formation of the rate-limiting aldehyde intermediate","volume":"46","author":"Hou","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2026.118887_bib41","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.112.044610","article-title":"Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004","volume":"40","author":"Hvenegaard","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2026.118887_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179134","article-title":"Poltheta inhibitor (ART558) demonstrates a synthetic lethal effect with PARP and RAD52 inhibitors in glioblastoma cells","volume":"25","author":"Barszczewska-Pietraszek","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118887_bib43","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s41467-024-46593-1","article-title":"Discovery of a small-molecule inhibitor that traps Pol\u03b8 on DNA and synergizes with PARP inhibitors","volume":"15","author":"Fried","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118887_bib44","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.jmedchem.5c02689","article-title":"Discovery of SY-589, a highly potent and orally bioavailable poltheta helicase inhibitor for the treatment of HR-Deficient tumors","volume":"69","author":"Ge","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118887_bib45","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12935-021-02178-2","article-title":"Knockdown of POLQ interferes the development and progression of hepatocellular carcinoma through regulating cell proliferation, apoptosis and migration","volume":"21","author":"Pan","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2026.118887_bib46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2021.07.013","article-title":"Selenium stimulates the antitumour immunity: insights to future research","volume":"155","author":"Razaghi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118887_bib47","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1021\/acs.jmedchem.3c02426","article-title":"Selenization of small molecule drugs: a new player on the board","volume":"67","author":"Moran-Serradilla","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118887_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118887_bib49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118887_bib50","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118887_bib51","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/genetics\/163.3.1031","article-title":"Phenotype-based identification of mouse chromosome instability mutants","volume":"163","author":"Shima","year":"2003","journal-title":"Genetics"},{"key":"10.1016\/j.ejmech.2026.118887_bib52","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1083\/jcb.201708069","article-title":"DNA damage-induced immune response: micronuclei provide key platform","volume":"216","author":"Gekara","year":"2017","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118887_bib53","first-page":"13","article-title":"Depletion of DNA polymerase theta inhibits tumor growth and promotes genome instability through the cGAS-STING-ISG pathway in esophageal squamous cell carcinoma","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.118887_bib54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:54:07Z","timestamp":1783169647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"alternative-id":["S0223523426003326"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118887","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of an orally bioavailable selenium-containing Pol\u03b8 inhibitor with a dual mechanism of DNA damage and immune activation for HR-deficient cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118887"}}